NASDAQ$PDSB
PDS Biotechnology Corporation · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
PDS Biotechnology reported its first quarter 2025 financial results and provided clinical programs and corporate updates.
PDS Biotechnology reported a net loss of $8.5 million for the first quarter of 2025, an improvement from the $10.6 million net loss in the same period last year, primarily due to increased benefit from income taxes and lower operating expenses. The company also highlighted progress in its clinical trials, including the initiation of the VERSATILE-003 Phase 3 trial and FDA clearance for a new IND application.
- Net loss for Q1 2025 was approximately $8.5 million, an improvement from $10.6 million in Q1 2024.
- Research and development expenses decreased to $5.8 million in Q1 2025 from $6.7 million in Q1 2024.
- Total operating expenses were $9.1 million in Q1 2025, down from $10.1 million in Q1 2024.
- The VERSATILE-003 Phase 3 clinical trial for Versamune® HPV in recurrent/metastatic HPV16-positive head and neck squamous carcinoma has initiated site activations.
Headline financials
Revenue & EPS history
PDS Biotechnology · Revenue · Quarterly
$0
Forward guidance
The company's forward-looking statements indicate continued focus on advancing its clinical programs, particularly the VERSATILE-003 Phase 3 trial, and managing its capital requirements. The success of these initiatives and future financing will be critical.
Tailwinds
- Initiation of VERSATILE-003 Phase 3 trial for HPV16-positive HNSCC, with site activations progressing.
- FDA Fast Track designation for Versamune® HPV and pembrolizumab in R/M HNSCC.
- FDA clearance of IND application for Versamune® MUC1 and PDS01ADC combination for colorectal carcinoma.
- Multiple abstracts selected for presentation at the 2025 ASCO Annual Meeting.
- Preclinical efficacy data for Infectimune® based universal flu vaccine featured in presentations.
Headwinds
- Dependence on additional financing to fund operations and complete product development.
- Risks that raising additional capital may restrict operations or require relinquishing rights to technologies.
- Limited operating history makes it difficult to evaluate prospects and business plan implementation.
- Uncertainty regarding the timing, pace of enrollment, and completion of clinical trials.
- Potential for actual results to differ materially from expectations due to various risks and uncertainties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+1.3%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+2.0%
Avg return
30 days after
52%
22 / 42 earnings
Positive
+55.0%
Q3 2022
Best reaction
-27.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.1% | +5.7% | -3.8% | |
| Q3 2025 | -12.2% | -18.2% | +1.0% | |
| Q2 2025 | -4.9% | +0.8% | -5.7% | |
| Q1 2025 | +4.8% | +15.0% | +37.8% | |
| Q4 2024 | +0.8% | -12.9% | +0.8% | |
| Q3 2024 | -27.2% | -24.0% | -33.2% | |
| Q2 2024 | -1.0% | +6.6% | +0.0% | |
| Q1 2024 | -0.3% | -4.4% | -21.2% | |
| Q4 2023 | -11.6% | -10.3% | -27.0% | |
| Q3 2023 | +20.3% | +19.7% | +2.9% | |
| Q2 2023 | +21.2% | +17.1% | +13.2% | |
| Q1 2023 | +5.0% | +14.9% | -7.4% | |
| Q4 2022 | +2.2% | -4.7% | +1.0% | |
| Q3 2022 | +55.0% | +54.5% | +64.3% | |
| Q2 2022 | +0.2% | +1.9% | -21.7% | |
| Q1 2022 | -14.3% | +15.2% | -21.7% | |
| Q4 2021 | -1.1% | -1.0% | -12.1% | |
| Q3 2021 | -1.6% | +2.2% | -14.6% | |
| Q2 2021 | +0.6% | -6.5% | +44.5% | |
| Q1 2021 | +8.2% | +27.0% | +174.1% | |
| Q4 2020 | +1.9% | -5.3% | +2.3% | |
| Q3 2020 | -0.5% | -1.9% | +3.8% | |
| Q2 2020 | -5.1% | +0.7% | -26.5% | |
| Q1 2020 | -2.3% | -1.8% | +39.3% | |
| Q4 2019 | +2.3% | -7.9% | +29.6% | |
| Q3 2019 | +0.0% | -14.0% | -3.4% | |
| Q2 2019 | +1.1% | -0.5% | -15.2% | |
| Q1 2019 | +43.0% | +18.6% | +6.4% | |
| Q4 2018 | +3.8% | +2.6% | -1.7% | |
| Q3 2018 | -2.8% | -4.9% | -6.2% | |
| Q2 2018 | +1.3% | +0.0% | -4.3% | |
| Q1 2018 | -6.4% | -3.6% | -15.3% | |
| Q4 2017 | +1.5% | +9.4% | -92.2% | |
| Q3 2017 | +1.2% | -2.2% | -8.0% | |
| Q2 2017 | -1.2% | -3.1% | -2.0% | |
| Q1 2017 | +2.8% | +2.4% | +3.2% | |
| Q4 2016 | -9.5% | -8.8% | -7.1% | |
| Q3 2016 | -6.3% | -0.6% | +9.9% | |
| Q2 2016 | +1.9% | +0.1% | -4.6% | |
| Q1 2016 | -4.2% | — | — | |
| Q4 2015 | -14.2% | — | — | |
| Q3 2015 | +0.5% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro